---
title: "Weekly Recap | Kodiak Sciences +11.97%, closing in on record highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305536325.md"
description: "Kodiak Sciences (KOD) gained 11.97% on the week, closing at $111.19 and outperforming the S&P 500 by about 9.46 percentage points. The stock opened Monday at $101.72 and pushed higher through the week, hitting an intraday high of $112.79 on Friday before settling at $111.19. Weekly amplitude was 13.01%, while average daily volume of 788k shares ran about 17.7% below its median, suggesting a relatively light-volume rally. The close sits well above both the 20-day moving average of $97."
datetime: "2026-11-14T06:42:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305536325.md)
  - [en](https://longbridge.com/en/news/305536325.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305536325.md)
generator: "portal-rs"
---

# Weekly Recap | Kodiak Sciences +11.97%, closing in on record highs

## The Week

Kodiak Sciences (KOD) gained 11.97% on the week, closing at $111.19 and outperforming the S&P 500 by about 9.46 percentage points. The stock opened Monday at $101.72 and pushed higher through the week, hitting an intraday high of $112.79 on Friday before settling at $111.19. Weekly amplitude was 13.01%, while average daily volume of 788k shares ran about 17.7% below its median, suggesting a relatively light-volume rally. The close sits well above both the 20-day moving average of $97.61 and the 60-day line at $70.26, and far off the 60-day range low of $29.81.

## Key Events

Company news clustered in the back half of the week. The stock surged over 8% intraday on Monday and set fresh 52-week highs in after-hours trading on Tuesday and Wednesday. On Wednesday, Kodiak announced it will present at three upcoming investor conferences. Before Friday’s open, the company reported fiscal Q3 results: revenue of $0 and GAAP EPS of -$1.05, beating estimates by $0.01, though net loss widened as R&D expenses rose. On Saturday, UBS maintained its buy rating and lifted its price target to $150 from $120, while commentary asked whether Phase 3 eye drug results have shifted the investment narrative. There were no material filings during the week.

## Analyst Ratings

Seven brokers cover KOD, with 5 at buy, 1 at overweight, and 1 at hold; no one is at underweight or sell. The consensus rating is strong buy, and the consensus target of $129.5 sits about 16.5% above the latest close. Targets range from $103 to $150, with most of the dispersion on the upside. Within the biotech industry, KOD ranks 240th out of 514 names by rating, placing it near the middle of the group.

## The Week Ahead

Macro data dominates next week: the New York Fed manufacturing index lands on 16 November, followed by retail sales, industrial production, and the NAHB housing market index on 17 November. Company-specific catalysts are thin, with attention likely to stay on the UBS target hike and on how the Phase 3 eye drug data continues to be interpreted, plus any details from the investor conferences.

## In Short

KOD advanced this week against a backdrop of results and a broker target hike. The sell-side stance is positive, with the consensus target above the spot price, while the company remains pre-revenue with a widening net loss. Valuation is stretched by conventional measures—roughly 556x book and a negative P/E—and the latest session showed large-lot money as a net seller while smaller lots were net buyers. The key question going forward is whether Phase 3 data can support the current repricing and narrow the wide target spread.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [KOD.US](https://longbridge.com/en/quote/KOD.US.md)

## Related News & Research

- [Did Phase 3 Eye Drug Results Just Shift Kodiak Sciences (KOD) Investment Narrative?](https://longbridge.com/en/news/305493238.md)
- [KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones](https://longbridge.com/en/news/305683102.md)
- [Kodiak Sciences GAAP EPS of -$1.05 beats by $0.01](https://longbridge.com/en/news/305374957.md)
- [Gold Stocks Fall: What's Going On?](https://longbridge.com/en/news/306159306.md)
- [Kodiak Sciences (KOD) Could Be 23% Undervalued On Its Retina Pipeline Story](https://longbridge.com/en/news/304752600.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**